Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Masao Iwata
Observed name:
MASAO IWATA
Institution:
Eisai (Japan)
Observed institutions:
University of Tsukuba,
Mercian Corporation (Japan),
Eisai (Japan)
ORCID:
0009-0001-4217-6077
Observed ORCID:
0009-0001-4217-6077
OpenAlex ID:
A5113385628
Splicing factor SF3b as a target of the antitumor natural product pladienolide
2007
·
Yoshihiko Kotake
, Koji Sagane
, et al.
·
Nature Chemical Biology
·
732
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
2014
·
Osamu Tohyama
, Junji Matsui
, et al.
·
Journal of Thyroid Research
·
503
PDF
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
2013
·
Kiyoshi Okamoto
, Kotaro Kodama
, et al.
·
Cancer Letters
·
311
PDF
Pladienolides, New Substances from Culture of Streptomyces platensis Mer-11107 III. In Vitro and In Vivo Antitumor Activities
2004
·
YOSHIHARU MIZUI
, TAKASHI SAKAI
, et al.
·
The Journal of Antibiotics
·
201
PDF
Biological validation that SF3b is a target of the antitumor macrolide pladienolide
2011
·
Akira Yokoi
, Yoshihiko Kotake
, et al.
·
FEBS Journal
·
195
PDF
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling
2021
·
Kazuhiko Yamada
, Yusaku Hori
, et al.
·
Cancer Research
·
76
High antitumor activity of pladienolide B and its derivative in gastric cancer
2013
·
Momoko Sato
, Naoki Muguruma
, et al.
·
Cancer Science
·
59
PDF
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2016
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
·
Molecular Cancer Therapeutics
·
44
PDF
Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
2014
·
Yusuke Narita
, Kiyoshi Okamoto
, et al.
·
Molecular Cancer Therapeutics
·
34
PDF
Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
2015
·
Ken Ito
, Shusei Hamamichi
, et al.
·
Cancer Science
·
31
PDF
E7107, a new 7-urethane derivative of pladienolide D: Discovery of a novel antitumor agent
2004
·
Jun Niijima
, Yoshihiko Kotake
, et al.
·
Cancer Research
·
21
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024
·
Jason W.-L. Eng
, Yu Kato
, et al.
·
Cancer Research Communications
·
9
Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent
2017
·
Kazuhiko Yamada
, Yusaku Hori
, et al.
·
Cancer Research
·
6
Abstract 770: E7090: A potent and selective FGFR inhibitor with activity in multiple FGFR-driven cancer models with distinct mechanisms of activation
2015
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
·
Cancer Research
·
3
111 In‐encapsulated liposome‐distribution in mouse xenografts of human ovarian cancer
2016
·
Ken Ito
, Shusei Hamamichi
, et al.
·
Cancer Science
·
1
PDF
E7107: Antitumor activity on human SCLC and cervical cancer xenografts in relation to its potential predictive markers of response.
2007
·
Masao Iwata
, Toshimitsu Uenaka
, et al.
·
Cancer Research
·
1
Supplementary Figure S4 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Supplementary Figure S2 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Supplementary Table 1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Supplementary Figure S1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Supplementary Figure S3 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Correction: Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
·
Cancer Research Communications
PDF
Supplementary Figure S1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Supplementary Figure S4 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Supplementary Figure S3 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025
·
Jason W.-L. Eng
, Yu Kato
, et al.
Show more works
View as search
Works count:
84
Citation count:
2,227
H-index:
11
I10-index:
11
Year
Topic
Type